Search

Displaying results 5061 - 5070 of 10000 in total
  1. Drug

    SR 121463

    go.drugbank.com/drugs/DB05455
    Investigational

    It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH). … SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 (V1b) receptor subtype.

  2. Drug

    Oxantel

    go.drugbank.com/drugs/DB13670
    Investigational

    Oxantel is an anthelmintic drug that targets parasitic acetylcholine receptors.[A275093, A275098]

  3. Drug

    Umbilical Cord Blood Hematopoietic Stem Cells

    go.drugbank.com/drugs/DB15723
    Investigational

    From the UCB, mononuclear cells are isolated and cultured in medium, expanded, and differentiated into the desired cell type. … Specifically, the proliferation capacity of human umbilical cord blood mononuclear progenitor cells (HUCBC) are much higher than similar cells in bone marrow.

  4. Drug

    Epoetin delta

    go.drugbank.com/drugs/DB11624
    ApprovedWithdrawn

    Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.

  5. Drug

    TC-5231

    go.drugbank.com/drugs/DB05333
    Experimental

    TC-5231 is mecamylamine hydrochloride, the active ingredient in FDA-approved product, Inversine, but in a lower dose than Inversine. … TC-5231 is a small molecule that has been under investigation as an oral treatment for ADHD (Attention Deficit/Hyperactivity Disorder).

  6. Drug

    Phenoxypropazine

    go.drugbank.com/drugs/DB09251
    ApprovedWithdrawn

    It was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential. … Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging to the _hydrazine_ chemical class.

  7. Drug

    Col-118

    go.drugbank.com/drugs/DB05778
    Investigational

    It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue. … Col-118 is a unique formulation and presentation of Brimonidine, which is a selective alpha-2 adrenergic receptor agonist.

  8. Drug

    Cixutumumab

    go.drugbank.com/drugs/DB12250
    Investigational

    Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types. … Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.

  9. Drug

    G4544

    go.drugbank.com/drugs/DB05244
    Experimental

    G4544 is an oral gallium compound that enables oral absorption of the active ingredient contained in Ganite™ (gallium nitrate injection). … It targets bone tissue and is actively incorporated into bone mineral at sites where bone is metabolically active.

  10. Drug

    LIC-477

    go.drugbank.com/drugs/DB05363
    Experimental

    LIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.